Director Nachum Shamir filed a Form 4 with the SEC on November 12, 2026, reporting the exercise of Series A Warrants to acquire 16,336 ordinary shares of MediWound Ltd. (NASDAQ:MDWD) on November 10, 2026.
Key Highlights
- Warrant exercise: Nachum Shamir exercised 16,336 Series A Warrants on November 10, 2026, at an exercise price of $13.475 per share, paying the aggregate exercise price in cash.
- No shares sold: According to the filing, the reporting person did not sell any of the ordinary shares acquired upon the exercise.
- Post-transaction holdings: Following the transaction, Shamir directly holds 72,151 ordinary shares in Table I.
- Warrants extinguished: The Series A Warrants exercised had an expiration date of November 28, 2026, and the filing reports zero Series A Warrants remaining after the exercise.
- RSUs on record: The filing also notes 1,200 ordinary shares underlying RSUs granted March 4, 2026, vesting 100% on the one-year anniversary of the grant date.
- Stock options held: Shamir holds stock options covering a combined 72,141 ordinary shares across four separate grants, with exercise prices ranging from $11.885 to $18.54, reported for informational purposes with no transactions in the period.
MediWound Director Shamir Exercises Series A Warrants Before November 2026 Expiration
According to the Form 4 filing, Nachum Shamir, a director of MediWound Ltd. (NASDAQ:MDWD), exercised 16,336 Series A Warrants on November 10, 2026, to purchase 16,336 ordinary shares at an exercise price of $13.475 per share. The filing states that the aggregate exercise price was paid in cash, and that "no separate price was paid for the Series A Warrants upon exercise." The warrants carried an expiration date of November 28, 2026, and the filing records zero Series A Warrants remaining in Shamir's beneficial ownership following the transaction.
The filing reports that Shamir's direct beneficial ownership of ordinary shares stands at 72,151 following the warrant exercise. Additionally, 1,200 ordinary shares are listed separately, representing shares underlying RSUs granted on March 4, 2026, which vest 100% on the one-year anniversary of the grant date, according to the filing's explanation of responses.
Table II of the filing also discloses four stock option grants held directly by Shamir, with no transactions reported against those positions. The options carry exercise prices of $12.495, $11.885, $12.729, and $18.54, covering 28,571, 11,800, 12,570, and 9,200 ordinary shares respectively, with expiration dates ranging from August 17, 2032 to February 11, 2035. A fifth option grant covering 10,000 ordinary shares at $17.60 was granted March 4, 2026, with an expiration date of March 4, 2036, and vests 100% on the one-year anniversary of the grant date.
What Was Disclosed
Nachum Shamir, a director of MediWound Ltd., reported the exercise of 16,336 Series A Warrants at $13.475 per share on November 10, 2026, resulting in direct ownership of 72,151 ordinary shares. No shares acquired were sold. The filing also disclosed RSU and stock option holdings for informational purposes.




Please wait processing your request...